Endoscopy 2020; 52(S 01): S144-S145
DOI: 10.1055/s-0040-1704446
ESGE Days 2020 ePoster Podium presentations
Thursday, April 23, 2020 11:30 – 12:00 Endoscopic sleeve gastroplasty ePoster Podium 1
© Georg Thieme Verlag KG Stuttgart · New York

FIRST EXPERIENCES WITH THE ENDOSCOPIC SLEEVE GASTROPLASTY (ESG) WITH THE ENDOMINA-SYSTEM© AS A BRIDGE TO SURGERY FOR SUPEROBESE PATIENTS - A ONE-YEAR FOLLOW UP

F Prinz
1   University Hospital Augsburg, Gastroenterology, Augsburg, Germany
,
R Paschwitz
2   University Hospital Augsburg, Augsburg, Germany
,
T Kuegler
2   University Hospital Augsburg, Augsburg, Germany
,
S Wasserberg
2   University Hospital Augsburg, Augsburg, Germany
,
M Anthuber
2   University Hospital Augsburg, Augsburg, Germany
,
S Nau
1   University Hospital Augsburg, Gastroenterology, Augsburg, Germany
,
H Messmann
1   University Hospital Augsburg, Gastroenterology, Augsburg, Germany
,
S Gölder
1   University Hospital Augsburg, Gastroenterology, Augsburg, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
23 April 2020 (online)

Also available at
 

Aims According to the German guidelines, behavioral therapy and surgery are the first line treatment options for obesity. For superobese patients (BMI > 50 kg/m2) with multiple comorbidities, an endoscopic bridge to surgery to reduce the perioperative risk may be a further treatment option.

In our bariatric center, we investigated the Endoscopic Sleeve Gastroplasty (ESG) with the Endomina©-System (Endo Tools, Gosselies, Belgium). The aim being to investigate clinical performance and adverse events of an ESG prior to bariatric surgery.

Methods Follow-up of weight loss in kg, reduction of Body Mass Index (BMI) in kg/m2, total body weight loss (TBWL) and excess weight loss (EWL) in percent three, six and twelve months after ESG were recorded. All adverse events were documented and graded.

Results From August 2018 to October 2019, n=6 patients were treated with the Endomina©-System. Median body weight was 161 kg with a median BMI of 59.9 kg/m2. Median body weight was 138.5 kg, 133.5 kg and 110.6 kg three, six and twelve months after treatment respectively. Median BMI three, six and twelve months after treatment was 51.5 kg/m2, 49.6 kg/m2 and 38.7 kg/m2respectively. Median TBWL was 8.9 % after three months, 12.3 % after six months and 24.8 % twelve months after treatment. Median EWL three, six and twelve months after treatment was 16.5 %, 22.6 % and 48.2 % respectively.

One patient was lost to follow-up. One patient did not achieve a satisfactory weight loss six months after treatment and received a laparoscopic sleeve-gastrectomy. All other patients are currently reducing weight. No severe adverse events did occur.

Conclusions ESG with Endomina© is an effective, minimal-invasive procedure for the treatment of superobese patients after which bariatric surgery can be performed. ESG may substitute intragastric balloon implantation as a bridge to surgery in superobese patients.